Eterna Therapeutics Valuation
| ERNA Stock | USD 0.29 0.03 9.38% |
Eterna Therapeutics seems to be overvalued based on Macroaxis valuation methodology. Our model computes the value of Eterna Therapeutics from reviewing the firm fundamentals such as Operating Margin of (104.91) %, shares outstanding of 51.37 M, and Shares Owned By Institutions of 10.99 % as well as analyzing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Eterna Therapeutics' valuation include:
Price Book 2.0975 | Enterprise Value 45.9 M | Enterprise Value Ebitda (0.29) | Price Sales 102.7176 | Enterprise Value Revenue 73.8685 |
Overvalued
Today
Please note that Eterna Therapeutics' price fluctuation is out of control at this time. Calculation of the real value of Eterna Therapeutics is based on 3 months time horizon. Increasing Eterna Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Eterna Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Eterna Stock. However, Eterna Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.29 | Real 0.31 | Hype 0.41 | Naive 0.48 |
The real value of Eterna Stock, also known as its intrinsic value, is the underlying worth of Eterna Therapeutics Company, which is reflected in its stock price. It is based on Eterna Therapeutics' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Eterna Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Eterna Therapeutics helps investors to forecast how Eterna stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Eterna Therapeutics more accurately as focusing exclusively on Eterna Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Eterna Therapeutics' intrinsic value based on its ongoing forecasts of Eterna Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Eterna Therapeutics' closest peers. If more than one evaluation category is relevant for Eterna Therapeutics we suggest using both methods to arrive at a better estimate.
Eterna Therapeutics Cash |
|
Eterna Valuation Trend
Comparing Eterna Therapeutics' enterprise value against its market capitalization is a good way to estimate the value of Eterna Therapeutics uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Eterna Therapeutics Total Value Analysis
Eterna Therapeutics is currently estimated to have valuation of 45.93 M with market capitalization of 16.64 M, debt of 41.84 M, and cash on hands of 19.41 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Eterna Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
45.93 M | 16.64 M | 41.84 M | 19.41 M |
Eterna Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Eterna Therapeutics has an asset utilization ratio of 0.14 percent. This suggests that the Company is making $0.001384 for each dollar of assets. An increasing asset utilization means that Eterna Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Eterna Therapeutics Ownership Allocation
Eterna Therapeutics holds a total of 51.37 Million outstanding shares. Roughly 89.01 percent of Eterna Therapeutics outstanding shares are held by general public with 10.99 % by other corporate entities. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.Eterna Therapeutics Profitability Analysis
The company reported the previous year's revenue of 68 K. Net Loss for the year was (21.67 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Eterna Therapeutics' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Eterna Therapeutics and how it compares across the competition.
About Eterna Therapeutics Valuation
The stock valuation mechanism determines Eterna Therapeutics' current worth on a weekly basis. Our valuation model uses a comparative analysis of Eterna Therapeutics. We calculate exposure to Eterna Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Eterna Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -168 K | -159.6 K | |
| Pretax Profit Margin | (366.49) | (348.17) | |
| Operating Profit Margin | (357.43) | (339.56) | |
| Net Loss | (366.44) | (348.12) | |
| Gross Profit Margin | (2.84) | (2.70) |
Eterna Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 5.3 M |
Eterna Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Eterna Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Eterna we look at many different elements of the entity such as Eterna's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Eterna Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Eterna Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Eterna Therapeutics' worth.Complementary Tools for Eterna Stock analysis
When running Eterna Therapeutics' price analysis, check to measure Eterna Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eterna Therapeutics is operating at the current time. Most of Eterna Therapeutics' value examination focuses on studying past and present price action to predict the probability of Eterna Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eterna Therapeutics' price. Additionally, you may evaluate how the addition of Eterna Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |